A systems biology approach to identify key targets in KRAS/BRAF-mutated colorectal cancer.

ABSTRACT:

Background

KRAS and BRAF mutations are critical oncogenic drivers in colorectal cancer (CRC), with distinct molecular and clinical implications.

Methods

To uncover genes differentially expressed between these mutations, we compared KRAS G12D- and BRAF V600E-mutated CRC cell lines. Protein-protein interaction (PPI) network construction, pathway enrichment, survival analysis, and drug target screening were performed to identify therapeutic opportunities.

Results

Ten hub genes-TNF, IL1B, FN1, EGF, IFI44L, EPSTI1, AHR, COL20A1, CDH1, and SOX9-were identified as critical in KRAS-driven CRC. Enrichment analysis highlighted immune and inflammatory pathways, including "SARS-CoV-2 Signaling" and "Macrophage Stimulating Protein Signaling," as well as cellular processes like "Po

SUBMITTER: Shiravi S 

PROVIDER: S-EPMC12630477 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature